Press Release EU ZA

Avicanna Expands its Partnership with Viola Brands to the United Kingdom

Published

2 years ago

February 11, 2023

admin

The prescription products will be commercialized in partnership with IPS Pharma, an established company with more than 20 years of experience with unlicensed medicines.

TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has entered into a new sub-license agreement with VB Brands California LLC (“Viola Brands”) and Player Holdings LLC to exclusively commercialize its Viola-branded products in the United Kingdom territory (“UK”) where the company has entered into a sub-licensing agreement with Vertical Pharma Resources Limited T/A IPS Pharma (“IPS Pharma”) for the manufacturing and distribution of the products.

Expanding from the initial partnership in Canada where Avicanna successfully launched 9 SKUs of Viola-branded products across medical and adult use channels, the two companies have opened a new territory with their expansion into the UK. Starting late Q1 2023, Viola’s purpose-driven vision, rooted in social equity and social justice will be available to patients in the UK through the exclusive licensing agreement.

To facilitate the expansion, Avicanna has entered a sub-licensing agreement with IPS Pharma, a local pharmaceutical distribution company with more than 20 years of experience with unlicensed medicines to support the launch of the product offerings. The initial products will be manufactured in the UK under GMP guidelines and distributed through IPS’ Pharma’s existing network of pharmacies via medical prescription under the Special Access Program.

The initial products offered in the UK will include proprietary formulations of vaporizers in THC-dominant and balanced CBD:THC ratios and will be supported by medical education and training.

“We are thrilled to be extending our partnership with Al Harrington and the Viola team and expanding our high-quality products to patients in an exciting new international market. We are also looking forward to building new relationships and potential collaborations with the medical community in the United Kingdom as we have in other markets,” stated Aras Azadian.

Al Harrington, NBA veteran, Founder & CEO of Viola Brands commented, “I was inspired to start Viola when I saw how cannabis was able to heal my grandmother. Since then, our mission has been to help and empower as many people as possible and I’m so proud we’re now able to share our products with patients in the UK, with the help of our partners at Avicanna.”

The UK government legalized the use of cannabis in 2018, after the cases of two epileptic children benefited from using cannabis brought increased public attention to the issue. Medical cannabis can be prescribed by specialists as unlicensed medicines in the UK called CBPM (cannabis-based product for medicinal use).

The CBPM definition is necessarily broad to take account of the range of preparations which are cannabis-based that have been used for therapeutic purposes and to ensure that raw products/ingredients and intermediate products are captured. This is essential to ensure that where there is a clinical need, a patient will be able to access appropriate cannabis-based medicines and/or products can be made to meet any prescription.¹

To its knowledge, the Company carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:

Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.

Pharmaceutical Pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first pharmaceutical preparation (Trunerox™) is in the drug registration stage in South America.

Click to watch Avicanna’s Corporate Video 2022

SOURCE Avicanna Inc.

About IPS Pharma
IPS Pharma is an independent pharmaceutical services company operating in three main areas in the UK: Unlicensed medicines (Unlicensed Imports and Specials), Clinical Trials and Special Obtains. With more than 20 years in the market IPS has become a leading pharmaceutical manufacturer in the UK with the capability to deliver over 20,000 formulations for unlicensed medicines as well as Investigational Medical product (IMP) and comparators for clinical trials. IPS is audited and licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) and is also a member of the Association of Pharmaceuticals Unlicensed medicines Manufacturers (APSM).

In addition, IPS Pharma has been one of the first companies to offer medical cannabis to patients in the UK and has earned a leading position in the growing medical cannabis market in the United Kingdom.

About Viola
Founded in 2011 by NBA veteran Al Harrington, Viola is one of the nation’s leading producers and licensed wholesalers of premium quality cannabis products. The brand is named after and inspired by Al’s grandmother who suffers from glaucoma and diabetes, finding solace in cannabis remedies. Viola has integrated the latest cutting-edge technology with its own proprietary procedures designed for every stage of the cultivation, extraction and production process. The company is known for its wide variety of product offerings, from high-quality flower to premier butane extracts and operates in California, Colorado, Michigan, Oregon, and Oklahoma.

Through education, equitable offerings, expungement, and incubation programs, Viola’s mission is to increase minority representation, facilitate community building and provide greater employment opportunities to Black and other minority communities in cannabis. Viola intends to expand the reach of Viola into Canada with educational initiatives to increase the awareness of safe cannabis use.

Source link

Press Release

Aurora Cannabis and Vectura Fertin Pharma announce commercial collaboration

Published

1 month ago

August 4, 2024

admin

Aurora Cannabis Inc., a leading Canadian-based global medical cannabis company, and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, have announced that Aurora has entered into a commercial collaboration with Cogent International Manufacturing Ltd., a wholly-owned subsidiary of Vectura Fertin Pharma.

Through this arrangement, Cogent will initially launch its newly developed CBD lozenge on Aurora’s Canadian medical cannabis patient platform, giving access to patient feedback which will be used to validate the product proposition and patient responses to the product while building real-world patient data for future analysis.

Following the successful launch of the CBD lozenge, the two companies may explore opportunities regarding the potential commercialisation of other Vectura Fertin Pharmamedical cannabis products in Canada.

“We are excited about this commercial collaboration that will allow Aurora to leverage its industry-leading patient platform in Canada to support advancements in medical cannabis, as well as to provide our patients with access to Vectura Fertin Pharma’s new CBD lozenge,” said Miguel Martin, CEO for Aurora. “As a global leader in the manufacturing of pharmaceutical-grade medical cannabis, we are pleased to see increased interest in the possibilities of medical cannabis as part of healthcare options made available to Canadians.”

Michael Kunst, CEO for Vectura Fertin Pharma, said: “At Vectura Fertin Pharma, we are committed to building a pipeline of innovation, based on scientific rigor, to improve unmet medical and health needs. We are delighted to be working with the Aurora team who share our high standards for safety and quality, and our strong focus on improving people’s lives.

“Through this strategic collaboration, the Aurora platform will enable us to bring our new CBD lozenge, as prescribed by a healthcare professional, to the largest patient base in Canada, and to both study its impact and validate the product proposition through the generation of real-world patient data.”

The agreement between Aurora and Cogent is expected to have an initial term of 24 months, with a target of launching CBD containing products on Aurora’s Canadian medical cannabis marketplace, starting with a CBD lozenge.

The products will be manufactured, packaged and labelled by Cogent for sale and distribution by Aurora through its leading direct-to-patient e-commerce sales channel, requiring minimal additional capital investment by Aurora. The expected launch of the first SKU in market is targeted for later in 2024.

https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/latest-pharmaceutical-manufacturing-news/aurora-cannabis-and-vectura-fertin-pharma-announce-commercial-collaboration/

Source link

Press Release

Lyphe and Gro-Vida Announce Partnership

Published

3 months ago

June 15, 2024

admin

Lyphe Clinic has announced a partnership with Gro-Vida, a licensed medical cannabis cultivar. This collaboration marks a significant step forward in advancing patient care and access to high-quality medical cannabis products within the UK.

By forming a strategic partnership with Gro-Vida, Lyphe Clinic aims to further enhance its commitment to providing superior care and uninterrupted access to medical cannabis treatments for its patients.

Sophie Gamwell, Managing Director at Lyphe Clinic, expressed her enthusiasm about the partnership, stating: “We are delighted to join hands with Gro-Vida to ensure seamless access to medical cannabis for our patients. Guaranteeing a continuous and reliable supply of medication is paramount for their well-being, and this partnership enables us to fulfil that commitment.”

Mallory Bodnar, Managing Director at Gro-Vida, commented:“Our partnership with Lyphe Clinic represents a significant step forward in our shared commitment to enhancing patient well-being. We are thrilled about this collaboration, which embodies our joint dedication to elevating standards of care. Together, we are ensuring that patients have access to high-quality, consistent medical cannabis.”

Through this partnership, Lyphe Clinic patients will benefit from a streamlined medical cannabis supply chain, ensuring consistent access to their prescribed medication. Additionally, the collaboration will empower Lyphe Clinic to exercise greater control over the quality and cost of the medical cannabis provided to its patients, ultimately enhancing the overall patient experience.

Source link

Press Release

Akanda Corp. Announces Closing of the Sale of RPK to Somai

Published

5 months ago

April 14, 2024

admin

London, United Kingdom–(Newsfile Corp. – April 11, 2024) – On April 1, 2024, Akanda Corp. (NASDAQ: AKAN) (“Akanda” or the “Company”), an international medical cannabis company, completed the transaction with SOMAÍ Pharmaceuticals Ltd. (the “Buyer”) for the sale of RPK, its indirect wholly-owned Portuguese subsidiary.

Pursuant to the provisions set forth in the definitive share purchase agreement, the cash purchase price is Two Million United States Dollars (USD $2,000,000). In addition SOMAÍ is assuming up to One Millions Euros of current liabilities and RPK’s debt with the senior secured lender Bank, Caixa Agricola. In total the Buyer is assuming approximately 4,000,000 Euros of debt. In accordance with the terms of the proposed transaction, a deposit amounting to Five Hundred Thousand United States Dollars (USD $500,000) was released from a joint escrow account and the remainder of the purchase price was paid directly to the Company.

Akanda Corp. is now in a stronger financial position and will continue to strengthen its presence in the global cannabis market through its wholly-owned United Kingdom (UK) subsidiary, Canmart. Canmart is a licensed importer and distributor of Cannabis-Based Products for Medicinal use (CBPMs) in the UK. and provides third party and specialist import and distribution services for Schedule 2 products including CBPM’s. Canmart continues to work further with premium product suppliers to bring safe, effective and required products to market that patients demand, and working with existing and new clinical cannabis operations in the UK to provide third party products. Beyond its operations in the UK, Akanda is also developing the Gabriola Green Project in British Columbia, Canada. This farming property is set to host facilities for the production of tetrahydrocannabinol (THC) and cannabinoid (CBD) products, reflecting the Company’s commitment to expanding its footprint and advancing its projects across both Europe and North America. The Company has initiated the regulatory framework to begin CBD cultivation with a future outlook towards THC.

Interim CEO and Executive Director, Katie Field commented, “Akanda is in a strong position to execute a new sustainable strategic direction. The company is in a better cash position and has eliminated most of its debt. We are looking forward to the Company’s anticipated growth.”

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company’s securities, nor shall there be any sale of such securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

Source link